JCO Global Oncology最新文献

{"title":"Treatment Patterns and Outcomes of Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Tanzania.","authors":"Lemi Ndugumbi Zinga, Queen Godfrey Tarimo, Kelvin Mbelekwa, Mamsau Twalib Ngoma, Emmanuel L Lugina","doi":"10.1200/GO-24-00612","DOIUrl":"10.1200/GO-24-00612","url":null,"abstract":"<p><strong>Purpose: </strong>Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (HER2+BC) is linked to poorer outcomes. Trastuzumab is the standard treatment, but its high cost limits access in resource-limited settings. This study evaluated the treatment patterns and survival outcomes of patients with HER2 BC in Tanzania.</p><p><strong>Materials and methods: </strong>A retrospective hospital-based study was conducted between January 2018 and May 2021 at two prominent public tertiary hospitals in Tanzania. The primary outcome was the 5-year overall survival (OS) rate. Independent variables included demographics, clinical characteristics, and treatment patterns. Survival analysis was conducted using the Kaplan-Meier method. The log-rank test was used in univariate analysis, whereas multivariate Cox regression was used in multivariate analysis.</p><p><strong>Results: </strong>A total of 169 patients with nonmetastatic HER2+BC were included, with a median age of 50 years. Most patients were estrogen receptor-positive (50.3%) and diagnosed with stage III BC (58.6%). About 70.4% of patients received trastuzumab, whereas neoadjuvant chemotherapy was administered to 24.3%, and 95.9% underwent mastectomy. Trastuzumab was primarily used in the adjuvant setting rather than the neoadjuvant setting and was more accessible to patients with higher socioeconomic status. The 5-year OS was 65%, with a median survival of 72 months. Trastuzumab reduced the mortality risk by 74%. Extended therapy with trastuzumab benefited patients with hormone receptor-negative HER2+BC more than those who were hormone receptor-positive. Advanced-stage disease increased mortality risk, whereas postmenopausal status and nonsmoking were associated with lower mortality. A higher Eastern Cooperative Oncology Group score (>1) was associated with an increased mortality risk.</p><p><strong>Conclusion: </strong>Trastuzumab significantly improves OS in resource-limited settings, particularly in patients with hormone receptor-negative HER2+BC. There are disparities in access to trastuzumab in Tanzania.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400612"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12494324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social Determinants Associated With the Advanced-Stage Diagnosis of Breast Cancer.","authors":"Madonna A Fekry, Loay Kassem, Justin C Yang, Hamdy A Azim","doi":"10.1200/GO-25-00108","DOIUrl":"https://doi.org/10.1200/GO-25-00108","url":null,"abstract":"<p><strong>Purpose: </strong>The majority of Egyptian patients with breast cancer (BC) present at advanced stages. We examined the sociodemographic and clinical factors associated with late presentation of BC.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted on patients who presented with BC between 2011 and 2020. Logistic regression analysis was used to examine the association between sociodemographic factors and advanced-stage BC.</p><p><strong>Results: </strong>This cohort included 1,953 patients with a median age of 52 years. Among them, 1,098 (56.2%) patients were diagnosed at early stages, whereas 855 (43.8%) were diagnosed at advanced stages. Univariable logistic regression revealed several factors associated with advanced BC, including having a negative family history of BC (odds ratio [OR], 1.27 [95% CI, 1.05 to 1.54]), having no job (OR, 1.28 [95% CI, 1.06 to 1.53]), being married (OR, 1.27 [95% CI, 1.02 to 1.57]), rural residence (OR, 1.27 [95% CI, 1.02 to 1.57]), having more than three children (OR, 1.42 [95% CI, 1.15 to 1.75]), higher Ki67% score (OR, 1.01 [95% CI, 1.00 to 1.01]), having human epidermal growth factor receptor 2-overexpressed or triple-negative BC subtypes (OR, 1.44 [95% CI, 1.16 to 1.79]), and having tumor grade 2/3 (OR, 4.12 [95% CI, 1.58 to 10.77 and OR, 1.44 [95% CI, 1.16 to 1.79], respectively). In the multivariable logistic regression model, only higher Ki67% (adjusted odds ratio [aOR], 1.01 [95% CI, 1.00 to 1.02]), having no job (aOR, 1.44 [95% CI, 1.10 to 1.90]), and rural residence (aOR, 1.88 [95% CI, 1.03 to 3.42]) were significantly associated with advanced BC.</p><p><strong>Conclusion: </strong>This study concluded that having no job and rural residence are strongly associated with advanced BC. Raising public awareness is essential to encourage early detection of BC.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500108"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative Training to Improve Childhood Cancer Knowledge Among Primary Health Care Providers: Evaluating a Blended Learning Program in Kenya.","authors":"Larissa Klootwijk, Lilian Apadet Osamong, Ibrahim El Salih, Rana Dandis, Sally Kimaiyo, Terry A Vik, Steven van de Vijver, Gertjan Kaspers, Festus Njuguna","doi":"10.1200/GO-25-00071","DOIUrl":"https://doi.org/10.1200/GO-25-00071","url":null,"abstract":"<p><strong>Purpose: </strong>Early detection and timely referral are vital to improving childhood cancer outcomes in low- and middle-income countries. However, training primary health care providers (HCPs) remains challenging because of limited time and resources. This study assesses the knowledge of primary health care workers after a blended learning program on childhood cancer and examines impact on referrals.</p><p><strong>Methods: </strong>A prospective study in Bungoma, Kenya (January-June 2023), evaluated the first blended pediatric oncology training. Knowledge was assessed via a semistructured questionnaire before (pretest), after (post-test), and 6 months later (evaluation test). Median scores were compared across subgroups (eg, sex, worker type, facility level, training attendance, and short message service learning appreciation). Referral numbers from Bungoma County to the referral hospital were analyzed before and after the program.</p><p><strong>Results: </strong>Of the 3,040 participants, 496 (16%) completed the blended learning program. Median pretest score was 7 (IQR, 6-8), which significantly increased to eight (IQR, 7-9) in post-test (<i>P</i> < .001) but significantly decreased to six (IQR, 5-7) in evaluation test (<i>P</i> < .001). Community health volunteers consistently scored significantly lower than other HCPs on all three test points (<i>P</i> < .001, <i>P</i> < .001, and <i>P</i> = .028). Live training attendance did not significantly affect test scores. In total, 181 participants (36%) reported suspecting childhood cancer cases since the launch of the program. However, this is not reflected in the annual average of 14 referrals in the 2 years after the program.</p><p><strong>Conclusion: </strong>The blended learning program improved knowledge initially but declined significantly after 6 months. Digital learning showed promise, yet low referral rates highlight the need to address barriers to effective referrals.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500071"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Where the Borders Bleed: Festivals, Fragility, and the Footfall of a Young Soldier's Return.","authors":"Sameer Rastogi, Nihanthy D Sreenath","doi":"10.1200/GO-25-00239","DOIUrl":"10.1200/GO-25-00239","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500239"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer.","authors":"Anita Ramesh","doi":"10.1200/GO-25-00115","DOIUrl":"https://doi.org/10.1200/GO-25-00115","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500115"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Genomic Profiling of Anaplastic Thyroid Cancer Identifies Alterations in <i>THRA</i>, a Potential Modifier of Cellular Plasticity.","authors":"Vaishakhi Trivedi, Vanita Noronha, Munita Bal, Pratik Chandrani, Disha Poojary, Elveera Saldanha, Anuradha Choughule, Priyanka Pange, Vinod Gupta, Nandini Menon, Vijay Patil, Minit Shah, Pankaj Chaturvedi, Kumar Prabhash, Amit Dutt","doi":"10.1200/GO-24-00610","DOIUrl":"https://doi.org/10.1200/GO-24-00610","url":null,"abstract":"<p><strong>Purpose: </strong>Lineage-specific cellular plasticity is one of the emerging hallmarks of cancer. The undifferentiated state of anaplastic thyroid cancer (ATC) represents an instance of cellular plasticity where lineage-specific molecular markers are underacknowledged. In this study, we identified recurrent mutations in the thyroid hormone receptor α (<i>THRA</i>) gene, which may play a role in lineage-specific cellular plasticity in ATC.</p><p><strong>Materials and methods: </strong>We performed whole-exome sequencing and targeted sequencing of 68 formalin-fixed paraffin-embedded orphan tumors of ATC from Indian patients.</p><p><strong>Results: </strong>Our analysis reveals the hallmark mutations in <i>TP53</i> (approximately 42%), <i>BRAF</i> (approximately 10.3%), <i>KRAS</i> (approximately 2.9%), <i>NRAS</i> (29.4%), <i>HRAS</i> (23.5%), <i>NF1</i> (1.5%), <i>AKT1</i> (approximately 2.9%), and <i>PIK3CA</i> (approximately 1.5%) genes. Interestingly, we found significant mutations in <i>THRA</i> (approximately 11%) in our cohort, unlike the White population, which is a substantial gene in the thyroid cell's differentiation process. <i>THRA</i> mutations co-occur with TP53 and other hallmark genes, which suggests a synergetic molecular mechanism in phenotypic change in ATC.</p><p><strong>Conclusion: </strong>Our data reveal the significant association of <i>THRA</i> mutations potentially influencing cellular plasticity in a subset of patients with ATC.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400610"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Decayed, Missing, Filled Teeth Score With the Risk for Buccal Mucosa Cancer, Stratified on Tobacco and Alcohol Use: A Multicenter Case-Control Study From India.","authors":"Grace Sarah George, Arjun Singh, Romi Moirangthem, Aniket Patil, Gayathri B Pullat, Sakshi Sagare, Manigreeva Krishnatreya, Aseem Mishra, Rahul Sonwane, Bayan Hosseini, Anil Chaturvedi, Pankaj Chaturvedi, Rajesh Dikshit, Sharayu Mhatre","doi":"10.1200/GO-25-00119","DOIUrl":"10.1200/GO-25-00119","url":null,"abstract":"<p><strong>Purpose: </strong>Buccal mucosa cancer (BMC), the most prevalent oral cancer (OC) site, is a multifactorial disease. With relatively high prevalence of periodontal diseases because of poor oral hygiene practices, oral health indicators remain an area of exploration in the Indian context for its association with BMC.</p><p><strong>Methods: </strong>A total of 1,673 histologically confirmed cases and 1,601 frequency-matched controls from a hospital-based, multicenter case-control study was analyzed for the risk of BMC because of the oral hygiene indicators-denture use, number of decayed, missing, and filled teeth, and the Decayed, Missing, Filled Teeth (DMFT) score. Logistic regression models, adjusted for potential confounders like age, sex, rural-urban status, education, and tobacco and alcohol use (duration and frequency), were used to estimate odds ratios (ORs) and 95% CI. Analysis was further stratified on tobacco chewing and smoking.</p><p><strong>Results: </strong>We obtained an increased risk of decayed (OR_{>2 decayed teeth}, 1.53; 95% CI, 1.09 to 2.16), missing teeth (OR_{>2 missing teeth}, 2.59; 95% CI, 1.99 to 3.37), and high DMFT scores (OR_{>3 DMFT score}, 2.07; 95% CI, 1.62 to 2.66). Similar results were observed on the stratified analysis. Protective effect was observed for teeth filling (OR_{>2 teeth-fillings}, 0.59; 95% CI, 0.34 to 1.03) and denture use (OR_{ever versus never used dentures}, 0.63; 95% CI, 0.47 to 0.85).</p><p><strong>Conclusion: </strong>Our findings suggest that DMFT score is associated with the risk of BMC and should be included in national oral health programs for prevention of OCs, along with other indicators of oral hygiene.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500119"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Immunotherapy for Hepatocellular Carcinoma in Clinical Practice: A Brazilian Multicenter Study.","authors":"Leonardo Gomes da Fonseca, Cecília Souza Freire, Rodrigo Antonio Vieira Guedes, Marcos Castro Lyra, Maria Ignez Freitas Melro Braguiroli, Mariana Bruno Siqueira, Maria De Lourdes Lopes de Oliveira, Alexandre de Mendonça Palladino, Henry Luiz Najman, Rodrigo Tancredi, Duilio Reis Da Rocha Filho, Markus Cavalcante Gifoni, Guilherme Luiz Stelko Pereira, Marcela Crosara Alves Teixeira, Lucila Soares Da Silva Rocha, Raimundo Paraná, Paulo Marcelo Hoff","doi":"10.1200/GO-25-00128","DOIUrl":"10.1200/GO-25-00128","url":null,"abstract":"<p><strong>Purpose: </strong>Immunotherapy-based combinations have shown promising survival benefits in patients with hepatocellular carcinoma (HCC) included in clinical trials. However, real-world data are needed to assess the effectiveness and safety of these therapies in diverse clinical settings and regions.</p><p><strong>Patients and methods: </strong>We conducted a Brazilian multicenter observational study, including 163 patients with unresectable or metastatic HCC treated with immunotherapy between August 2020 and March 2024 in 14 centers. Patient characteristics, treatment outcomes, and adverse events were analyzed. Survival outcomes were assessed using the Kaplan-Meier method, and Cox regression identified predictors of survival.</p><p><strong>Results: </strong>Most patients were male (85.3%), with a median age of 72 years. Liver cirrhosis was present in 70.6%, and 77% had Barcelona Clinic Liver Cancer stage C. Immunotherapy was predominantly first-line (91.4%), with atezolizumab plus bevacizumab as the most common regimen (77.9%). The median treatment duration was 4.9 months, and the median overall survival (OS) was 14.7 months (95% CI, 11.6 to 24.5), with 12- and 24-month survival rates of 57.0% and 41.4%, respectively. Considering the patients with Child-Pugh A and performance status 0-1 (n = 116), the median OS was 20.6 months (95% CI, 12.4 to 25.8). Immune-related adverse events occurred in 19.6%, mainly thyroid disorders and skin manifestations. Adverse events related to bevacizumab included variceal (n = 6) and other bleeding events (n = 7). Albumin-bilirubin grade 2 to 3, metabolic dysfunction-associated steatotic liver disease, and esophagogastric varices were independently associated with reduced OS.</p><p><strong>Conclusion: </strong>In a real-world setting, immunotherapy-based treatments demonstrated effectiveness and safety profiles consistent with clinical trials, although survival was influenced by liver function, etiology, and baseline variceal status. These findings highlight the relevance of baseline liver disease characteristics in guiding immunotherapy in HCC and underscore the need for tailored management strategies.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500128"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Ethnicity on Breast Cancer Outcome: A Systematic Review and Meta-Analysis of Randomized Phase III Trials of the Last Decade.","authors":"Emma Zattarin, Luca Moscetti, Elisa D'Agostino, Alberto Bertolotti, Isabella Sperduti, Chiara Chiavelli, Fabio Canino, Federico Piacentini, Laura Cortesi, Massimo Dominici, Angela Toss","doi":"10.1200/GO-25-00139","DOIUrl":"https://doi.org/10.1200/GO-25-00139","url":null,"abstract":"<p><strong>Purpose: </strong>It remains uncertain whether ethnicity affects the benefit derived from novel breast cancer (BC) treatments. Thus, we conducted a systematic review and meta-analysis to evaluate the heterogeneity of treatment efficacy across different ethnic groups, in both the advanced BC (aBC) setting and the early BC (eBC) setting.</p><p><strong>Methods: </strong>We systematically searched PubMed, Embase, and Scopus for phase III randomized controlled trials (RCTs) leading to BC drug approval between 2013 and 2023 that had available hazard ratios (HRs) for outcome according to ethnicity. We excluded nonrandomized studies. We compared the three most represented ethnic groups, Whites, Asians, and Blacks, among themselves and with other underrepresented groups (UGs). The pooled HRs and 95% CI in ethnic subgroups were calculated using a random-effects model, and the heterogeneity between the estimates was assessed with an interaction test.</p><p><strong>Results: </strong>Among 23 selected RCTs (14,000 patients) in the aBC setting, 20 provided HRs (95% CI) for progression-free survival (PFS) in the subgroup of Whites, 17 for Asians, four for Blacks, and 23 for non-Asians (Whites + all non-Asian UG) or non-Whites (Asians + all non-Asian UG). Risk of bias was low for all the included RCTs. The HRs for PFS with experimental versus control drugs were 0.62 (95% CI, 0.57 to 0.68) for Whites, 0.54 (95% CI, 0.44 to 0.66) for Asians, and 0.54 (95% CI, 0.34 to 0.85) for Blacks with no significant interethnic difference (<i>P</i> = .233 for Whites <i>v</i> Asians, <i>P</i> = .564 for Whites <i>v</i> Blacks, <i>P</i> = .992 for Asians <i>v</i> Blacks). Similarly, Whites versus non-Whites and Asians versus non-Asians showed no significantly different magnitude of benefit (<i>P</i> = .406 and <i>P</i> = .226, respectively). No differences were observed in eBC trials either.</p><p><strong>Conclusion: </strong>These results offer reassurance for the broader applicability of clinical trial results despite ethnic imbalance.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500139"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Treatment Outcomes of Colorectal Cancer in Jordan, a Resource-Restricted Country.","authors":"Hikmat Abdel-Razeq, Maha Barbar, Sarah Abdel-Razeq, Fawzi Abuhijla, Issa Mohamad, Kamal Al-Rabi, Akram Al-Ibraheem, Hazem Hammad, Asem Mansour","doi":"10.1200/GO-25-00079","DOIUrl":"https://doi.org/10.1200/GO-25-00079","url":null,"abstract":"<p><strong>Purpose: </strong>Colorectal cancer is the second most prevalent cancer in Jordan and remains the second leading cause of cancer-related deaths in both men and women. This manuscript aims to explore the situation of colorectal cancer in Jordan, a resource-restricted country, and provide insights into clinical presentation and treatment outcomes.</p><p><strong>Materials and methods: </strong>We reviewed all reports from the Jordan Cancer Registry over the past 20 years. Treatment outcome data were obtained from the King Hussein Cancer Center (KHCC) registry since its inception in 2006 until August 2022. Overall survival (OS) was reported for the whole group and stratified by disease stage. Age-standardized incidence rates (ASIR) and mortality estimates were obtained from the latest GLOBOCAN reports.</p><p><strong>Results: </strong>During the study period, a total of 3,424 patients from the KHCC cancer registry were included in this analysis. Only a minority of the patients were diagnosed with early-stage disease, with 132 (3.9%) patients at stage I and 589 (17.2%) at stage II, whereas the majority presented with stage III (n = 1,383, 40.4%) and stage IV (1,131, 33.0%) disease. After a median follow-up of 49 months, the 5-year OS for the whole group was 53.9% (95% CI, 52.0% to 55.8%) and varied by disease stage; 87.7% (95% CI, 80.3% to 93.5%) for stage I, 84.7% (95% CI, 81.3% to 87.9%) for stage II, 69.9% (95% CI, 67.0% to 72.8%) for stage 3, and only 14.5% (95% CI, 12.2% to 16.9%) for patients with stage IV disease, <i>P</i> < .0001.</p><p><strong>Conclusion: </strong>One third of all patients with colorectal cancer are diagnosed with metastatic disease, which explains the lower survival rates observed compared with Western countries. Programs and initiatives focused on the prevention and early detection of colorectal cancer should be a national priority.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500079"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}